Hydrocortisone Hualan Pharmaceuticals

Hydrocortisone Hualan Pharmaceuticals is an oral glucocorticoid medication containing the active ingredient hydrocortisone. It is supplied by Hualan Pharmaceuticals and marketed in the European Union. The product is presented without a specified strength or dosage form, and it is classified under the ATC code H02AB02 as a systemic anti‑inflammatory agent. It belongs to the class of anti‑inflammatory and immunosuppressive drugs and is used under supervision for conditions requiring steroid therapy.

Hydrocortisone Hualan Pharmaceuticals is indicated for several clinical situations where glucocorticoid replacement or anti‑inflammatory action is required.

- Primary adrenal insufficiency (Addison’s disease) requiring cortisol replacement. - Acute adrenal crisis management. - Inflammatory disorders such as rheumatoid arthritis, ulcerative colitis, or severe dermatitis. - Allergic reactions including anaphylaxis adjunct therapy. - Certain autoimmune conditions where systemic steroid therapy is indicated. - Short‑term use for severe asthma exacerbations when oral steroids are required.

Like other systemic glucocorticoids, hydrocortisone may cause a range of adverse reactions, varying in frequency and severity.

Common: - Increased appetite or weight gain. - Mild insomnia or mood changes. - Elevated blood glucose levels, especially in diabetic patients. - Gastrointestinal discomfort such as dyspepsia. - Fluid retention causing mild edema. - Skin thinning or easy bruising. - Headache or dizziness.

Serious: - Severe hyperglycemia or new‑onset diabetes. - Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis leading to adrenal insufficiency on abrupt discontinuation. - Opportunistic infections or worsening of existing infections. - Severe psychiatric effects such as psychosis or depression.

When prescribing hydrocortisone, clinicians consider several precautionary measures to minimize risks and ensure safe use.

- Assess baseline blood glucose and monitor regularly in patients with diabetes or metabolic syndrome. - Evaluate for active infections; avoid initiating therapy in uncontrolled bacterial, viral, or fungal infections. - Use the lowest effective dose for the shortest duration to reduce the risk of HPA‑axis suppression. - Screen for osteoporosis risk factors and consider calcium/vitamin D supplementation in long‑term users. - Counsel patients about the potential for mood changes and advise reporting severe psychiatric symptoms. - Avoid use during pregnancy unless the benefit outweighs the risk, and discuss with a healthcare professional.

Hydrocortisone can alter the pharmacokinetics or pharmacodynamics of several other medicines, requiring attention to possible interactions.

Avoid: - Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) that may reduce hydrocortisone exposure. - Concurrent use with other systemic glucocorticoids, which can increase the risk of adrenal suppression and systemic side effects.

Use with caution: - Anticoagulants such as warfarin, where glucocorticoids may enhance anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that together increase the risk of gastrointestinal ulceration or bleeding. - Vaccines, especially live attenuated vaccines, as immunosuppression may diminish vaccine efficacy. - Diabetic medications, because hydrocortisone can raise blood glucose and may require dose adjustment.